CD8A and neoplasm: As shown in Fig. 4B and C, our results revealed that pBI-11 DNA vaccination by the customized needle-free biojector (intradermally or intramuscularly) produced comparable levels of circulating HPV antigen-specific CD8+ T cells relative to conventional needle injection of TC-1 tumor-bearing mice.